CIN-103

CIN-103 is a novel formulation of phloroglucinol modified to enhance the pharmacokinetic properties to sustain the therapeutic exposure for patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Phase 2

CIN-103
OVERVIEW:

CinPhloro’s CIN-103 is a novel, small-molecule, modified pulsatile-release formulation of phloroglucinol – a phenol-derivative with antispasmodic properties. In pre-clinical studies, CIN-103 has demonstrated to impact intestinal motility, secretion, pain, spasms & inflammation.

 

Phloroglucinol is approved in several countries in Europe for the treatment of gastrointestinal disorders.

 

Employing an extrusion-spheronization process, CinPhloro’s scientific and pharmacology team went through an extensive formulation process to reach a desired pharmacokinetic profile by combining immediate and delayed release technology.

 

CIN-103 has progressed from concept through Phase I Multiple Ascending Dose (MAD) trials demonstrating the desired PK profile. Phase I results demonstrated evidence of enhanced PK release profile based upon the novel CinPhloro formulation as well as decreased GI motility, secretion, pain, spasm and inflammation.

 

CIN-103 will be studied in additional clinical trials to be initiated in 2024.

IBS-D
Metrics:

Prevalence between 10%-15% in North America

Affects approximately 16.2M in the US

Most common reason for a referral to a gastroenterologist

REASONS
TO BELIEVE

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES